Dexamethasone suppression test as an aid for selection of specific antidepressant drugs in patients with endogenous depression.
The dexamethasone suppression test (DST) and response to two different antidepressant drugs (maprotiline as a specific noradrenergic, and amitriptyline as a predominantly serotoninergic drug) were investigated in 44 endogenously depressed female inpatients. The more anxious and/or agitated patients were mostly treated with amtiriptyline, the non-anxious and retarded patients with maprotiline. It was found that among maprotiline responders (N = 15) there were significantly more abnormal DSTs and postdexamethasone serum cortisol levels were significantly higher than among amitriptyline responders (N = 16). On the other hand, DST abnormalities among amitriptyline non-responders (N = 10) were similar to those among maprotiline responders. The results confirm earlier reports by Brown et al. (1980), Ettigi et al. (1983) and Fraser (1983) and indicate that abnormal DST may identify the "noradrenergic" subtype of endogenous depression and that the DST represents a good way of selecting a specific antidepressant drug for the treatment of endogenously depressed patients.
D000328:Adult; D000368:Aged; D000639:Amitriptyline / Q000627:therapeutic use*; D000873:Anthracenes / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D003866:Depressive Disorder / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D003907:Dexamethasone; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D008376:Maprotiline / Q000627:therapeutic use*; D008875:Middle Aged
D000873:Anthracenes; D000639:Amitriptyline; D008376:Maprotiline; D003907:Dexamethasone; D006854:Hydrocortisone